|
US7192584B2
(en)
*
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
CA2441228A1
(en)
*
|
2001-03-23 |
2002-10-03 |
Aphton Corporation |
Combination treatment of pancreatic cancer
|
|
US20090191232A1
(en)
*
|
2001-05-04 |
2009-07-30 |
Gevas Philip C |
Combination therapy for the treatment of tumors
|
|
KR20040049830A
(ko)
*
|
2001-07-09 |
2004-06-12 |
애프톤 코포레이션 |
간, 폐 및 식도의 암 및 전암 상태의 치료 및 예방
|
|
US20060165675A1
(en)
*
|
2002-08-02 |
2006-07-27 |
Richman-Eisenstat Janice Beth |
Modulation of mesenchymal cells via iga-receptors
|
|
CN1781023A
(zh)
*
|
2003-03-28 |
2006-05-31 |
埃弗顿有限公司 |
胃泌素激素免疫测定
|
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
EP1570858A1
(en)
*
|
2004-03-05 |
2005-09-07 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Monovalent ligand of the FCalphaRi receptor as an anti-inflammatory agent
|
|
AU2005228897B2
(en)
*
|
2004-03-29 |
2009-12-10 |
Cancer Advances, Inc. |
Monoclonal antibodies to gastrin hormone
|
|
JP2008513536A
(ja)
|
2004-09-22 |
2008-05-01 |
レセプター バイオロジックス インコーポレイテッド |
プロガストリンに対するモノクローナル抗体
|
|
JP5129122B2
(ja)
*
|
2005-04-26 |
2013-01-23 |
トリオン ファーマ ゲーエムベーハー |
癌治療のための抗体およびグルココルチコイドの組み合わせ
|
|
ES2460517T3
(es)
|
2005-07-25 |
2014-05-13 |
Emergent Product Development Seattle, Llc |
Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
|
|
EP2418223A3
(en)
|
2006-06-12 |
2013-01-16 |
Emergent Product Development Seattle, LLC |
Single-chain multivalent binding proteins with effector function
|
|
EP2184608B1
(en)
|
2007-08-23 |
2016-10-05 |
LSI Medience Corporation |
Non-specific reaction inhibitor
|
|
PT2132228E
(pt)
|
2008-04-11 |
2011-10-11 |
Emergent Product Dev Seattle |
Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
|
|
EP2127666A1
(en)
*
|
2008-05-28 |
2009-12-02 |
Drug Discovery Factory B.V. |
Method for the treatment or prophylaxis of chronic inflammatory diseases
|
|
WO2011088219A2
(en)
*
|
2010-01-13 |
2011-07-21 |
The Uab Research Foundation |
Therapeutics and processes for treatment of immune disorders
|
|
MX339621B
(es)
*
|
2010-04-13 |
2016-06-02 |
Celldex Therapeutics Inc * |
Anticuerpos que se unen a cd27 humano y uso de los mismos.
|
|
US9850296B2
(en)
|
2010-08-10 |
2017-12-26 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Erythrocyte-binding therapeutics
|
|
US9517257B2
(en)
|
2010-08-10 |
2016-12-13 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Erythrocyte-binding therapeutics
|
|
CA2807942C
(en)
|
2010-08-10 |
2021-07-27 |
Ecole Polytechnique Federale De Lausanne |
Erythrocyte-binding therapeutics
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
EP2465536A1
(en)
*
|
2010-12-14 |
2012-06-20 |
CSL Behring AG |
CD89 activation in therapy
|
|
JP6602012B2
(ja)
*
|
2012-02-10 |
2019-11-06 |
シアトル ジェネティクス インコーポレーテッド |
Ｃｄ３０＋癌の検出と治療
|
|
EP2636681A1
(en)
|
2012-03-09 |
2013-09-11 |
CSL Behring AG |
Process for enriching IgA
|
|
RU2644240C2
(ru)
|
2012-03-09 |
2018-02-08 |
Цсл Беринг Аг |
Композиции, содержащие секреторноподобные иммуноглобулины
|
|
EP2636684A1
(en)
|
2012-03-09 |
2013-09-11 |
CSL Behring AG |
Prevention of infection
|
|
US10946079B2
(en)
|
2014-02-21 |
2021-03-16 |
Ecole Polytechnique Federale De Lausanne |
Glycotargeting therapeutics
|
|
US10046056B2
(en)
|
2014-02-21 |
2018-08-14 |
École Polytechnique Fédérale De Lausanne (Epfl) |
Glycotargeting therapeutics
|
|
US10953101B2
(en)
|
2014-02-21 |
2021-03-23 |
École Polytechnique Fédérale De Lausanne (Epfl) |
Glycotargeting therapeutics
|
|
CA2946064C
(en)
|
2014-02-21 |
2023-09-26 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Glycotargeting therapeutics
|
|
US10668147B2
(en)
*
|
2015-03-25 |
2020-06-02 |
Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. |
Anti-CD89 cytotoxic complex
|
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
|
MX2018003292A
(es)
|
2015-09-21 |
2018-08-01 |
Aptevo Res & Development Llc |
Polipéptidos de unión a cd3.
|
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
|
JP7083819B2
(ja)
*
|
2016-09-30 |
2022-06-13 |
セントレ ナショナル デ ラ レセルシュ シャンティフィク |
細胞マーカー
|
|
US12188935B2
(en)
|
2016-09-30 |
2025-01-07 |
Centre National De La Recherche Scientifique |
Method for the evaluation of antiretroviral therapy (ART) effectiveness in HIV-1 CD4+CD89+ cellular reservoirs
|
|
CA3046489A1
(en)
|
2016-12-07 |
2018-06-14 |
Progenity Inc. |
Gastrointestinal tract detection methods, devices and systems
|
|
US11168147B2
(en)
|
2016-12-23 |
2021-11-09 |
Novartis Ag |
Factor XI antibodies and methods of use
|
|
US20210138213A1
(en)
|
2017-03-30 |
2021-05-13 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
|
JP7469225B2
(ja)
|
2017-06-15 |
2024-04-16 |
キャンサー アドヴァンシーズ インク． |
腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法
|
|
US12150978B2
(en)
|
2017-06-15 |
2024-11-26 |
Cancer Advances Inc. |
Compositions and methods for preventing tumors and cancer
|
|
US11253579B2
(en)
|
2017-06-16 |
2022-02-22 |
The University Of Chicago |
Compositions and methods for inducing immune tolerance
|
|
US10882907B2
(en)
|
2017-06-21 |
2021-01-05 |
Gilead Sciences, Inc. |
Multispecific antibodies that target HIV GP120 and CD3
|
|
KR20210011919A
(ko)
|
2018-04-17 |
2021-02-02 |
셀덱스 쎄라퓨틱스, 인크. |
항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
|
|
AU2019265734B2
(en)
|
2018-05-09 |
2026-03-19 |
Anokion Sa |
Compositions and methods concerning immune tolerance
|
|
WO2019246317A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue originating from the endoderm
|
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
CN116726361A
(zh)
|
2018-11-19 |
2023-09-12 |
比奥拉治疗股份有限公司 |
用生物治疗剂治疗疾病的方法和装置
|
|
WO2021119482A1
(en)
|
2019-12-13 |
2021-06-17 |
Progenity, Inc. |
Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
|
|
US20230242646A1
(en)
*
|
2020-04-21 |
2023-08-03 |
Jjp Biologics Sp. Z O.O. |
Humanized Anti-Human CD89 Antibodies and Uses Thereof
|
|
AU2021357841A1
(en)
|
2020-10-08 |
2023-06-15 |
Affimed Gmbh |
Trispecific binders
|
|
US20230399407A1
(en)
*
|
2020-11-06 |
2023-12-14 |
Korea University Research And Business Foundation |
Fc alpha receptor binding antibody
|
|
KR102766045B1
(ko)
*
|
2020-11-06 |
2025-02-10 |
고려대학교 산학협력단 |
Fc 알파 수용체 결합력이 향상된 항체
|
|
KR102855679B1
(ko)
*
|
2020-11-06 |
2025-09-04 |
고려대학교 산학협력단 |
Fc 알파 수용체 결합 항체
|
|
KR102853685B1
(ko)
*
|
2020-11-06 |
2025-09-01 |
고려대학교 산학협력단 |
Fc 알파 수용체 결합력이 증진된 항체
|
|
JP2024529381A
(ja)
|
2021-07-30 |
2024-08-06 |
アフィメド ゲーエムベーハー |
デュプレックスボディ
|
|
CN121263441A
(zh)
|
2023-04-19 |
2026-01-02 |
森特萨制药(英国)有限公司 |
可活化的双特异性抗cd89和抗pd-l1蛋白质及其用途
|
|
CN117890576A
(zh)
*
|
2023-12-12 |
2024-04-16 |
深圳市陆为生物技术有限公司 |
一种检测CD89-IgA免疫复合物的试剂、方法及其应用
|
|
WO2025218725A1
(zh)
*
|
2024-04-18 |
2025-10-23 |
徕特康(苏州)生物制药有限公司 |
靶向cd20和cd89的髓细胞衔接子抗体及其用途
|
|
WO2026002175A1
(zh)
*
|
2024-06-27 |
2026-01-02 |
无锡徕特康生物科技有限公司 |
靶向ilt7和cd89的髓细胞衔接子抗体及其用途
|